(TTS) following vaccination to prevent coronavirus | Thrombocytopenia syndrome

Thrombotic Thrombocytopenia Syndrome (TTS) has emerged as a new adverse event following immunization in individuals vaccinated with COVID-19 ...Home/Publicationsdetail/Guidanceforclinicalcasemanagementofthrombosiswiththrombocytopeniasyndrome(TTS)followingvaccinationtopreventcoronavirusdisease(COVID-19)Download(2.1MB)OverviewThromboticThrombocytopeniaSyndrome(TTS)hasemergedasanewadverseeventfollowingimmunizationinindividualsvaccinatedwithCOVID-19non-replicantadenovirusvector-basedvaccines(AstraZenecaCOVID-19ChAdOx-1vaccineandJohnson&Johnson(J&J)JanssenCOVID-19Ad26.COV2-Svaccine).TTSisaseriousandlife-threateningadverseevent. WHOhasissuedthisinterimemergencyguidancetoincreaseawarenessaboutTTSinthecontextofCOVID-19vaccinationandhelphealthcareprovidersintheassessmentandmanagementofpotentialTTScases.KnowledgeaboutTTSfollowingvaccinationwithaCOVID-19adenovirusvector-basedvaccineisrapidlyevolving.WHOwillcontinuetomonitorthesituationcloselyforanychangesthatmayaffectthisinterimguidanceandwillupdatetheguidanceasneeded. WHOTeamPharmacovigilanceNumberofpages64ReferencenumbersWHOReferenceNumber:WHO/2019-nCoV/TTS/2021.1CopyrightSomerightsreserved.


常見健康問答


延伸文章資訊